Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma

NCT05656833 | Unknown DMC FDA Device

• 1 other identifier: SterlingIRB Study #9727
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine (Cyspera) alone in the treatment of melasma. The main questions it aims to answer are

• If melasma treatment with topical cysteamine cream is more effective when used with the Clear \& Brilliant® Permea laser
• The safety \& efficacy of melasma treatment in various skin types using the Clear \& Brilliantt® Permea laser in combination with topical cysteamine. Participants will
• Come into our office for an initial screening appointment to determine if participant is eligible for the study
• Come in for 3 laser treatments, 4 weeks apart, on 1 side of the face
• Use the study provided Cyspera topical cream every day on the entire face for the 12 weeks on the study. Researchers will compare the side of the participants face not treated with laser to the side of the face treated with laser. The participants will be using Cyspera on both sides of their face.

Conditions

Melasma

Keywords

Facial Melasma; Cyspera; Clear & Brilliant Laser; Laser; Melasma

Outcome Measures

Primary Outcomes (1)

• The primary objective of our study is to determine the efficacy of combined topical cysteamine cream with a 1927 diode non-ablative laser (Clear + Brilliant Permea®; Solta Medical, Inc.), compared to topical cysteamine alone in the treatment of melasma.

  Photographic assessment by two blinded dermatologists will measure changes will assess improvement in melasma by modified Melasma Area and Involvement Index (mMASI). Total mMASI score ranges from 0 - 24, with a higher score indicating more involvement and/or severity of melasma

  12 Weeks

Study Arms (2)

Fractional 1927nm Low-Powered Diode Laser combined with Topical Cysteamine

ACTIVE COMPARATOR

One side of the face of participants will be randomized to receive fractional 1927nm Low-Powered Diode Laser in combination with topical cysteamine. There are 3 total treatments with the laser, in combination with using the topical cysteamine cream every day for the duration of the study (12 weeks)

Device: Fractional 1927nm Low-Powered Diode Laser; Other: Topical Cysteamine

Topical Cysteamine Alone

ACTIVE COMPARATOR

The other side of the face that is not randomized to receive laser treatment will be subject to treatment with the topical cysteamine cream alone. Participants will use the topical cysteamine cream every day for the duration of the study (12 weeks).

Other: Topical Cysteamine

Interventions

Fractional 1927nm Low-Powered Diode Laser DEVICE

Clear \& Brilliant Permea® Laser used on the side of the face randomized to receive laser

Fractional 1927nm Low-Powered Diode Laser combined with Topical Cysteamine

Topical Cysteamine OTHER

Topical Cysteamine cream will be used on the entire face.

Fractional 1927nm Low-Powered Diode Laser combined with Topical Cysteamine; Topical Cysteamine Alone

Eligibility Criteria

• Age: 18 Years - 74 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy subjects of Skin Type I-VI females.
• Subjects must be between 18 and 74 years of age, and must have visible melasma on the face.
• Subjects must read, understand, and sign the Informed Consent.
• Subjects must be willing and able to comply with all follow-up requirements.

You may not qualify if:

• Subjects must not have active or localized or systemic infections.
• Subjects must not be immunocompromised.
• Subjects must not have a coagulation disorder, and must not be using anticoagulation -medications.
• Subjects must not have history of surgical or cosmetic treatment, including prior skin lightening agents, microneedling or microdermabrasion, or laser or light-based therapies, to the planned treatment areas in the prior 8 weeks.
• Subjects must not have photosensitivity or allergy.
• Subjects must not be mentally incompetent.
• Subjects must not be pregnant or breastfeeding.
• History of skin cancer or pre-cancerous lesions in the treatment area
• Subjects must not be currently using aspirin or antioxidants.
• Subjects must not refuse to sign the Informed Consent document and/or refuse to comply with all follow-up requirements.
• Subjects must never have had gold therapy.
• Subjects must never have had radiation therapy to the face. Recent or current suntan or sunburn within 2 weeks.
• Clinically dysplastic nevi in the treatment area.
• Subjects must not have had collagen, other methods of tissue augmentation, botox, chemical peels, dermabrasion, or resurfacing within the last year.
• Oral retinoid (Accutane or Soriatane) or photosensitizing drugs, e.g. Declomycin®, a tetracycline with light absorption in the range of 400 to 450 nm use within 24 months of study entry.

Sponsors & Collaborators

• UnionDerm: lead
• Solta Medical: collaborator
• Skin of Color Society: collaborator
• Scientis: collaborator

Study Sites (1)

UnionDerm

New York, New York, 10003, United States

RECRUITING

Related Links

• Contact / Official Website for UnionDerm

MeSH Terms

Conditions

Melanosis; Margins of Excision

Interventions

Cysteamine

Condition Hierarchy (Ancestors)

Hyperpigmentation; Pigmentation Disorders; Skin Diseases; Skin and Connective Tissue Diseases; Morphological and Microscopic Findings; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Mercaptoethylamines; Ethylamines; Amines; Organic Chemicals; Sulfhydryl Compounds; Sulfur Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Photographic assessment by two blinded dermatologists will measure changes will assess improvement in melasma by mMASI score. In addition, an investigator quartile improvement score from baseline to week 12 (0 - 0%, no improvement; 76%-100% - very significant improvement) will be assessed.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Single Center, Prospective, With Before-After Analysis

Study Record Dates

• First Submitted: December 6, 2022
• First Posted: December 19, 2022
• Study Start: October 28, 2022
• Primary Completion: April 1, 2023
• Study Completion: July 1, 2023
• Last Updated: December 19, 2022

Record last verified: 2022-12

Locations

US (1)